This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ANXA3 / Annexin A3 · IHC design guide
Design Immunohistochemistry for ANXA3
Plan ANXA3 paraffin-section IHC around variable cytoplasmic staining and strongly stained endocrine cells in the appendix and duodenum (HPA tissue IHC). Use those cell populations as positive references and titrate the IHC-validated antibody at 0.5–1 μg/ml (datasheet A04796).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ANXA3 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Variable cytoplasmic staining in most tissues (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic staining varies; endocrine cells can stain strongly (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6 HIER, heat-mediated (datasheet A04796) | |
| Positive control | Appendix+4 more · see all | |
| Negative control | Adrenal gland+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A04796) | |
| Caveat | Cell-specific staining may be missed when scoring whole sections (HPA tissue IHC) | |
| Regulation | Expression regulation unreported (UniProt) | |
| Isoform / epitope | No annotated isoforms; mature chain spans residues 2–323 (UniProt) |
Section 1
Recommended ANXA3 IHC & IF Protocols
The catalog antibody’s IHC-P protocol (datasheet: A04796) is accompanied by published ANXA3 staining protocols for colon carcinoma (PMC9273664) and interspinous ligament (PMC9019158).
| Sample | Paraffin-embedded human intestinal cancer tissue; fixative not specified (datasheet A04796) |
| Fixation | Image fixative and duration unreported (datasheet A04796); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6, 20 min (datasheet A04796) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A04796) |
| Primary antibody | Rabbit anti-ANXA3, 0.5-1μg/ml (datasheet A04796) |
| Primary incubation | Overnight at 4 °C (datasheet A04796) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A04796) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ANXA3-positive staining in endocrine cells of appendix (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression at variable levels in most tissues. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated citrate pH 6 retrieval (datasheet: A04796); the colon carcinoma protocol also reports microwave citrate retrieval for 15 min (PMC9273664).
Section 2
What Is the Expected ANXA3 Staining Pattern?
For paraffin-section IHC, expect ANXA3 staining in the cytoplasm at variable levels across tissues (HPA: tissue IHC profile; Enhanced reliability, with medium consistency against RNA data). High staining is reported in appendix and duodenum endocrine cells, kidney Bowman’s capsule, and lung alveolar type I cells (HPA: tissue IHC). ANXA3 has no annotated transmembrane segment (UniProt P12429: topology).
| Distinct cytoplasmic staining in appendix or duodenum endocrine cells, kidney Bowman’s capsule, or lung alveolar type I cells. | This matches the reported compartment and high-staining cell populations (HPA: tissue IHC). Judge each cell population separately: HPA describes variable expression across most tissues, so adjacent cells need not have equal signal (HPA: tissue IHC profile). |
| Predominantly nuclear staining in a paraffin section, with little cytoplasmic signal in the expected cells. | The compartment disagrees with HPA’s cytoplasmic tissue-IHC profile (HPA: tissue IHC). Treat it as suspect and check controls and detection conditions before scoring it as ANXA3. Plasma-membrane localization reported by ICC-IF does not establish a nuclear IHC pattern (HPA: subcellular ICC-IF). |
| Strong staining in a cell population reported as not detected, such as adrenal glandular cells or cardiomyocytes. | That result conflicts with the specified HPA observations (HPA: adrenal glandular cells and cardiomyocytes, Not detected). Assess cross-reactivity and endogenous chromogenic activity with appropriate controls (general IHC practice). A single discordant section does not establish true ANXA3 expression. |
| Diffuse color covers tissue structures or appears outside recognizable cells. | The distribution cannot be assigned confidently to ANXA3-positive cells. Check a no-primary control for detection background and review blocking, washing, and chromogen development (general IHC practice). HPA’s reported pattern is cellular and cytoplasmic in tissue IHC (HPA: tissue IHC profile). |
| No signal in an adequately sampled appendix or duodenum endocrine-cell population. | These are reported high-staining populations (HPA: appendix and duodenum endocrine cells, High). A blank result prompts review of tissue identity, antigen retrieval, antibody dilution, and detection controls (general IHC practice); it does not alone prove biological absence. |
💡Expected ANXA3 appearanceCall a paraffin-section result positive when recognizable expected cells show cytoplasmic signal, potentially high in the specified endocrine, Bowman’s capsule, or alveolar type I populations (HPA: tissue IHC); broad cell-free color or isolated nuclear staining is suspect against that profile (HPA: tissue IHC profile).
| Cell population and tissue | HPA reports High staining in four specified populations, Medium in bone marrow hematopoietic and several epithelial populations, and Not detected in selected cells (HPA: tissue IHC). Compare like cell populations rather than scoring the whole section uniformly. |
| Assay-specific compartment | Tissue IHC is described as cytoplasmic, while ICC-IF is mainly plasma-membrane localized with supported status (HPA: tissue IHC; HPA: subcellular ICC-IF). Use the pattern for the assay being interpreted; these observations do not establish an IF staining protocol. |
| Antibody validation | Both HPA013398 and HPA013431 have Enhanced IHC status (HPA: antibody validation). The tissue profile also carries an Enhanced reliability label with medium consistency against RNA data (HPA: tissue IHC); neither label guarantees every specimen will match. |
| Protein annotation | UniProt annotates no transmembrane segment, signal peptide, propeptide, or isoforms for ANXA3 (UniProt P12429: topology and processing). Those annotations do not resolve the IHC-versus-ICC-IF localization difference or specify antigen retrieval conditions. |
| Fixation sensitivity | Target-specific effects of fixation on ANXA3 staining are unreported in the supplied UniProt and HPA records. Optimize fixation and antigen retrieval as general IHC workflow variables, without treating either source as evidence for an ANXA3-specific effect. |
| Situation | Likely cause | Next action |
|---|---|---|
| The expected positive cells show no chromogenic signal. | The result conflicts with HPA’s High observations in appendix or duodenum endocrine cells, kidney Bowman’s capsule, and lung alveolar type I cells (HPA: tissue IHC); the failing step is undetermined. | Confirm the sampled cell population and run a known-positive section; review retrieval, catalog-antibody dilution, detection reagents, and chromogen development (general IHC practice). Do not infer an ANXA3-specific fixation effect from HPA. |
| A no-primary control develops widespread color. | The control points to background from the detection workflow rather than primary-antibody binding (general IHC practice). It cannot establish whether ANXA3 is present in the test section. | Review endogenous activity blocking appropriate to the chromogen system, secondary-reagent specificity, washing, and development time; repeat the control alongside the test section (general IHC practice). |
| Signal appears strong in adrenal glandular cells or cardiomyocytes. | Those populations are reported as Not detected (HPA: tissue IHC). Cross-reactivity or endogenous detection activity is possible, although a discordant stain alone cannot identify its cause. | Compare with a no-primary control and an expected positive population; inspect whether color follows cells or accumulates nonspecifically (general IHC practice). Record the discordance rather than assigning ANXA3 positivity immediately. |
| Most staining is nuclear or obscures cell boundaries. | A predominantly nuclear pattern differs from HPA’s cytoplasmic tissue-IHC profile (HPA: tissue IHC). Excess background or poor compartment resolution may prevent reliable scoring (general IHC practice). | Check counterstain contrast and no-primary background; review antibody concentration, washing, and chromogen development before interpreting localization (general IHC practice). |
| A weakly stained tissue seems inconsistent with bone-marrow RNA enrichment. | HPA calls ANXA3 RNA tissue enhanced in bone marrow but reports Medium staining in bone-marrow hematopoietic cells (HPA: tissue IHC and RNA specificity). RNA enrichment does not specify IHC staining intensity. | Score the hematopoietic cells against the reported Medium IHC observation and include a reported High-staining population as a process control (HPA: tissue IHC; general IHC practice). |
| IF/ICC Q: Is plasma-membrane signal compatible with ANXA3? | A: HPA reports mainly plasma-membrane localization in ICC-IF, with supported status (HPA: subcellular ICC-IF), while paraffin tissue IHC is described as cytoplasmic (HPA: tissue IHC). | Interpret each result using its assay-specific HPA observation. Consult the separate IF/ICC guide for that assay’s workflow; the tissue-IHC pattern does not supply an IF/ICC protocol. |
Experiment evidence
IHC & IF images showing ANXA3 staining
A04796 · IHCIHC analysis of ANXA3 using anti-ANXA3 antibody (A04796). ANXA3 was detected in paraffin-embedded section of human intestinal cancer tissue.
A04796 · IHCIHC analysis of ANXA3 using anti-ANXA3 antibody (A04796). ANXA3 was detected in paraffin-embedded section of human lung cancer tissue. Heat
M04796-2 · IHCIHC analysis of Annexin A3 using anti-Annexin A3 antibody (M04796-2). Annexin A3 was detected in a paraffin-embedded section of human placen
M04796-2 · IHCIHC analysis of Annexin A3 using anti-Annexin A3 antibody (M04796-2). Annexin A3 was detected in a paraffin-embedded section of human adenoc
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000138772-ANXA3/tissue/cerebral+cortex#imid_4790048
HPA · LungHuman Protein Atlas IHC, Lung. Source: https://www.proteinatlas.org/ENSG00000138772-ANXA3/tissue/lung#imid_4789927
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000138772-ANXA3/tissue/colon#imid_4789966
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000138772-ANXA3/tissue/liver#imid_4789967
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA013398; green = ANXA3, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA013398; green = ANXA3, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ANXA3 IHC & IF
🧪Start with appendix: endocrine cells should stain strongly (HPA: High in appendix endocrine cells). Use heart muscle as the negative tissue; cardiomyocytes should show no specific staining (HPA: Not detected in heart muscle cardiomyocytes). On the appendix slide, cells outside the endocrine compartment should show only background signal if used as internal negatives; confirm their status rather than assuming they lack ANXA3 (HPA: High is reported for endocrine cells only).
Positive control tissue: Appendix (Endocrine cells, HPA High)
Negative control tissue: Adrenal gland (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ANXA3 in A-431, U-251MG, U2OS, with annotated localisation: Plasma membrane (supported) (HPA subcellular).
Technical controls: Run no-primary (secondary-only), a host- and class-matched rabbit IgG isotype control matched to the primary’s clonality when known, and ANXA3 knockout control material (caption: rabbit primary; standard IHC practice). For SABC/DAB detection, quench endogenous peroxidase and check endogenous biotin background in the chosen tissue (caption: SABC/DAB; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A04796 tissue-IHC caption does not state a fixative (caption: fixative not stated). The paraffin-section example used citrate retrieval at pH 6 for 20 minutes; this supports a retrieval starting point but does not establish that retrieval is required for every specimen (caption: citrate retrieval). Frozen sections and IF cannot be judged easier from the supplied evidence; HPA reports ICC-IF images and mainly plasma-membrane localization, while endogenous peroxidase or biotin can complicate SABC/DAB interpretation (HPA: subcellular summary; caption: SABC/DAB; standard IHC practice).
HPA tissue IHC evidence for ANXA3
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Endocrine cells | High | Protein (IHC) | HPA → |
| Duodenum | Endocrine cells | High | Protein (IHC) | HPA → |
| Kidney | Bowman's capsule | High | Protein (IHC) | HPA → |
| Lung | Alveolar cells type I | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Not detected | Protein (IHC) | HPA → |
| Esophagus | Squamous epithelial cells | Not detected | Protein (IHC) | HPA → |
| Heart muscle | Cardiomyocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ANXA3 IHC Tips
These questions focus on interpreting ANXA3 staining in paraffin sections using chromogenic IHC, with one entry for IF/ICC planning.
Which antigen retrieval conditions should I start with for ANXA3 in paraffin sections?
Use heat-mediated citrate retrieval at pH 6 for 20 minutes as the starting condition for ANXA3 IHC in paraffin sections (datasheet A04796). The demonstrated workflow then used 10% goat serum and 1 μg/mL primary antibody overnight at 4°C, so keep those conditions stable while assessing retrieval (caption A04796). Compare retrieved sections with a no-primary control and a section processed without retrieval to distinguish signal gain from retrieval-associated background (standard IHC practice). Score the expected cell population and staining distribution, rather than choosing the hottest condition by overall DAB intensity (HPA tissue IHC; standard IHC practice). If signal remains weak, test a different retrieval buffer on adjacent sections as a documented fallback and recheck background (standard IHC practice).
How should I troubleshoot fixation-related loss of ANXA3 staining?
The selected image describes a paraffin-embedded section but does not state its fixative, so target-specific fixation sensitivity is unknown (caption A04796). Record the fixative, fixation duration, tissue thickness and processing history for each specimen before comparing staining intensity across cases (standard IHC practice). For an unexpectedly weak section, compare a well-preserved control section processed alongside it, using citrate at pH 6 for 20 minutes in both (datasheet A04796; standard IHC practice). Keep primary incubation at the demonstrated 1 μg/mL overnight at 4°C during that comparison (caption A04796). Neither the reported tissue staining nor ANXA3 topology or modifications establishes a fixation effect, so report any observed dependence as a result of your own comparison (HPA tissue IHC; UniProt P12429; standard IHC practice).
Should ANXA3 look cytoplasmic or membranous in chromogenic tissue IHC?
Assess cell identity and distribution before rejecting either cytoplasmic or membrane-associated staining: tissue IHC reports variable cytoplasmic expression, while subcellular IF supports a mainly plasma-membrane location (HPA tissue IHC; HPA subcellular). ANXA3 has no annotated transmembrane segment, so a membrane outline should not be interpreted as evidence that it spans the membrane (UniProt P12429 topology). Use high-staining reference populations, such as appendix endocrine cells or kidney Bowman's capsule, to assess whether your run detects plausible cellular signal (HPA: High in appendix endocrine cells; HPA: High in kidney Bowman's capsule). Examine adjacent morphology and no-primary controls before assigning a fine DAB rim to ANXA3, especially when the counterstain obscures compartment boundaries (standard IHC practice). Report cytoplasmic and peripheral staining separately when both occur (standard IHC practice).
Could isoforms or epitope accessibility explain discordant ANXA3 staining?
UniProt lists 0 isoforms for this record, so an isoform-specific explanation has no support in the supplied annotation (UniProt P12429 isoforms). The record identifies an N-acetylated residue at position 2 and a phosphothreonine at 267, but the selected antibody's epitope is not supplied (UniProt P12429 modified residues; caption A04796). Do not attribute loss of tissue staining to either modification without an epitope map and direct comparison (standard IHC practice). Compare adjacent sections with identical fixation and detection while varying retrieval or primary concentration one variable at a time (standard IHC practice). Document the antibody, tissue compartment and scoring rule so apparent epitope effects can be separated from changes in assay conditions (standard IHC practice).
How can I plan multiplex IF to clarify an ambiguous ANXA3 IHC pattern?
Use IF/ICC as a separate assay and co-stain ANXA3 with a validated marker for the cell population whose chromogenic signal is uncertain (standard IF practice). HPA reports high tissue IHC staining in appendix endocrine cells and supports a mainly plasma-membrane location by subcellular IF; these observations provide comparison points, not proof of colocalisation in your specimen (HPA tissue IHC; HPA subcellular). Choose spectrally separated fluorophores after checking tissue autofluorescence, and include single-stain and no-primary controls to assess bleed-through and background (standard IF practice). ANXA3 has no annotated transmembrane segment, and the antibody epitope's membrane-facing side is unspecified; compare mild permeabilisation with an unpermeabilised condition if membrane access matters (UniProt P12429 topology; caption A04796; standard IF practice).
What should I change when ANXA3 DAB staining is diffuse or widespread?
Run a no-primary section and inspect whether DAB appears in the same regions as the putative ANXA3 signal (standard IHC practice). The demonstrated method used 10% goat serum, 1 μg/mL primary antibody overnight at 4°C, a biotinylated secondary antibody and DAB detection (caption A04796). With that detection scheme, check endogenous peroxidase and biotin contributions using appropriate controls before changing the primary concentration (caption A04796; standard IHC practice). If control sections are clean, titrate primary antibody and shorten DAB development in matched sections while retaining citrate retrieval at pH 6 for 20 minutes initially (datasheet A04796; standard IHC practice). Judge improvement by cellular contrast, since HPA reports variable cytoplasmic expression across tissues (HPA tissue IHC; standard IHC practice).
How should I quantify ANXA3 staining across paraffin-section specimens? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring, because HPA reports variable cytoplasmic tissue staining while its subcellular IF supports a mainly plasma-membrane location (HPA tissue IHC; HPA subcellular). For a defined population, record the percentage of positive cells and staining intensity, then calculate an H-score if those categories are reproducible (standard IHC practice). For sparse positive cells, report positive-cell density per mm² of viable, analyzable tissue instead (standard IHC practice). Normalize counts to the number of eligible cells or viable tissue area, and keep section thickness, retrieval and DAB development comparable across specimens (standard IHC practice). Report cytoplasmic and peripheral scores separately and exclude necrotic or folded regions under a prespecified rule (standard IHC practice).
How do I distinguish true ANXA3 staining from tissue artefact?
Treat staining as more credible when it follows intact cell boundaries or cytoplasm in a plausible population and exceeds the corresponding no-primary control (HPA tissue IHC; HPA subcellular; standard IHC practice). HPA reports high signal in appendix endocrine cells and lung alveolar type I cells, but no detected signal in esophageal squamous epithelial cells; use these as contextual checks, not universal thresholds (HPA tissue IHC). A nuclear-only pattern lacks support from the supplied localisation evidence, which describes cytoplasmic tissue staining and a supported plasma-membrane IF location (HPA tissue IHC; HPA subcellular). Reassess edge-heavy staining, necrotic areas and diffuse DAB before calling positivity, and test endogenous peroxidase contributions with controls (standard IHC practice). Record the positive cell type and compartment alongside the final score (standard IHC practice).
Boster reagents
Best ANXA3 / Annexin A3 IHC Antibodies
ANXA3 antibodies have IHC images from paraffin sections of human intestinal cancer, placenta and mouse kidney (catalog image captions); IF/ICC is listed for PB9420, with no IF image supplied (catalog applications and images).
Real IHC data
Anti-Annexin A3/ANXA3 Antibody ®
Cat # A04796
Real IHC data
Anti-Annexin A3 Antibody ® (monoclonal, 2H3H8)
Cat # M04796-2
A04796 will render with IHC data from human intestinal cancer; its additional IHC images show human lung and mammary cancers and mouse kidney (A04796 image captions). M04796-2 will render with IHC data from human placenta; its additional images show human colon adenocarcinoma and thyroid cancer (M04796-2 image captions).
Which to pick: For paraffin section IHC across species, choose rabbit A04796: human and mouse staining is shown, and rat reactivity is listed (A04796 image captions; catalog reactivity). For human paraffin section IHC using a monoclonal antibody, choose mouse clone 2H3H8, M04796-2 (M04796-2 catalog clone and image captions). For IF/ICC, consider PB9420 at 5 μg/ml, while recognizing that IF/ICC is listed without an IF image; the fixative is unreported in the paraffin section captions for all three SKUs (PB9420 catalog applications and dilution; catalog image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P12429 (ANXA3_HUMAN, Annexin A3).
- Human Protein Atlas. ANXA3 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. ANXA3 subcellular location (ICC-IF): Mainly localized to the plasma membrane..
- Human Protein Atlas. ANXA3 antibody validation summary (2 antibodies).
- Expression of HIF-1α, ANXA3, CD133 and their associations with clinicopathological parameters in human colon carcinoma. Translational cancer research 2022 — PMC9273664.
- Overexpression of ANXA3 is an independent prognostic indicator in gastric cancer and its depletion suppresses cell proliferation and tumor growth. Oncotarget 2016 — PMC5349965.
- Annexin A3 as a Prognostic Biomarker for Breast Cancer: A Retrospective Study. BioMed research international 2017 — PMC5406736.
- Upregulated of ANXA3, SORL1, and Neutrophils May Be Key Factors in the Progressionof Ankylosing Spondylitis. Frontiers in immunology 2022 — PMC9019158.
- PubMed PMID:2968983 — UniProt-cited evidence.
- PubMed PMID:1830024 — UniProt-cited evidence.
- PubMed PMID:8276419 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ANXA3 (Annexin A3). Expected localisation Variable cytoplasmic staining in most tissues (HPA tissue IHC). Antigen retrieval: Citrate pH 6 HIER, heat-mediated (datasheet A04796). Validated IHC antibody: A04796 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Endocrine cells); negative Adrenal gland. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human intestinal cancer tissue; fixative not specified (datasheet A04796); 2. Fixation: Image fixative and duration unreported (datasheet A04796); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6 , 20 min (datasheet A04796); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A04796); 8. Primary antibody: Rabbit anti-ANXA3, 0.5-1μg/ml (datasheet A04796); 9. Primary incubation: Overnight at 4 °C (datasheet A04796). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A04796); Caveat: Cell-specific staining may be missed when scoring whole sections (HPA tissue IHC); Isoform / epitope: No annotated isoforms; mature chain spans residues 2–323 (UniProt); Regulation: Expression regulation unreported (UniProt). Evidence: UniProt P12429, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the plasma membrane., Datasheet A04796, PMC9273664, PMC9019158. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ANXA3/immunohistochemistry-ihc-guide.